How to Detect, Characterize, and Evaluate CAR-T Cell Therapies
Presenter: Dr Rajendra Kumari, Crown Bioscience
CAR-T cell therapy is a rapidly advancing I/O treatment approach, genetically modifying a patient’s own T cells to identify and eliminate specific antigen-expressing tumor cells. Strategies are now needed to optimize CAR-T cell therapy and extend durable responses to a wider population, including patients with solid tumors.
In this webinar, Dr Rajendra Kumari discusses the translational challenges in CAR-T cell therapy development, including toxicities such as CRS, an immunosuppressive TME, and monitoring persistence. She’ll explore how preclinical in vivo models and a novel rare cell analysis platform help overcome these issues to progress CAR-T cell therapy development.
Watch this Webinar to Learn:
- Where preclinical in vivo models fit in the refinement of CAR strategies
- The pros and cons of different preclinical models for CAR efficacy and safety assessment including xenograft, humanized, syngeneic, and transgenic models
- How to select and use patient-derived xenografts (PDX) expressing CAR targets to evaluate novel CAR-T cell therapy proof of concept
- How a novel multiparameter imaging and analysis platform enables more highly sensitive detection of rare cells such as CAR-T cells compared to conventional approaches
- How to determine CAR-T cell persistence in clinical samples using the rare cell analysis platform
Who Should Watch:
- Decision makers from biotechnology and pharmaceutical companies focused on CAR-T and cell therapy
- In vivo pharmacology researchers interested in CAR-T and cell therapy
- Preclinical and clinical scientists searching for a sensitive rare cell detection method
About The Presenter:
Dr Rajendra Kumari is the Global Head of Scientific Communications for Crown Bioscience, providing scientific guidance and communications on company products, services, and R&D.
Rajendra received her PhD from the University of Leicester in Molecular Pharmacology, following which she joined the lab of Prof. Sue Watson as a postdoctoral fellow in the Division of Pre-clinical Oncology, School of Clinical Sciences, University of Nottingham (UoN). In 2005, Rajendra took the role of Project and Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit where she built up and managed the portfolio of preclinical in vitro and in vivo projects, products, team and clients, as well as marketing and developing the commercial processes of PRECOS.
Rajendra’s expertise in cancer cell biology and model development helped to build PRECOS, develop an academic career as a lecturer in the School of Clinical Sciences, as well as co-founding the Ex Vivo Pharmacology Centre of Excellence (UoN), which recapitulates the tumor microenvironment through use of clinically-derived tissue. Rajendra was pivotal in the growth of the business unit and commercialization of research which led to the establishment of the spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director and co-founder, until merger with CrownBio in July 2013 where she then acted as GM/CSO for CrownBio UK for 4 years.
Rajendra is a member of the American Association of Cancer Research, British Association of Cancer Research, the NC3Rs Cancer Research Advisory Group, and has authored over 40 abstracts and publications.